Activity of 2-Aryl-2-(3-indolyl)acetohydroxamates against Drug-Resistant Cancer Cells
Citations Over TimeTop 10% of 2015 papers
Abstract
Many types of tumor, including glioma, melanoma, non-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically resistant to apoptosis induction and poorly responsive to current therapies with proapoptotic agents. In addition, tumors often develop multidrug resistance based on the cellular efflux of chemotherapeutic agents. Thus, novel anticancer agents capable of overcoming these intrinsic or developed tumor resistance mechanisms are urgently needed. We describe a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids that are active against apoptosis- and multidrug-resistant cancer cells as well as glioblastoma neurosphere stemlike cell cultures derived from patients. Thus, the described compounds serve as a novel chemical scaffold for the development of potentially highly effective clinical cancer drugs.
Related Papers
- → Function and Inhibitory Mechanisms of Multidrug Efflux Pumps(2021)207 cited
- → The role of RND-type efflux pumps in multidrug-resistant mutants of Klebsiella pneumoniae(2020)77 cited
- → Antimicrobial Resistance: Two-Component Regulatory Systems and Multidrug Efflux Pumps(2023)71 cited
- → A genetic platform to investigate the functions of bacterial drug efflux pumps(2022)45 cited
- Progress on Escherichia coli AcrAB-TolC Multidrug Efflux Pump and Its Regulation(2008)